Repligen (RGEN) Announces CEO Transition Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St futures tick up as investors weigh earnings; PayPal jumps
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise 1% as hostilities worsen in the Middle East
- ASML capacity upgrade soothes AI chip bottleneck fears
- Dollar steadies as Middle East escalation counters soft US inflation
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Repligen Announces CEO Transition Plan
June 13, 2024 7:00 AM EDTWALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors (Board) has approved the planned transition of Tony J. Hunt from Chief Executive Officer (CEO) to Executive Chair, effective September 1, 2024. The Companys Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current... More
